English to French Medical Medical: Pharmaceuticals genetics

Deux produits sont actifs dans la LMC : nilotinib et imatinib. Le nilotinib a la même efficacité que les patients LMC, au préalable, se soient montrés ou non résistants/intolérants à l'imatinib.
Ci-après le texte qui donne la logique de cette similiraté des résultats, mais que je ne comprends pas :
"The estimated percent of patients who achieved a major cytogenetic response and who did not discontinue nilotinib due to progression or death for at least 6 months after achievement of response was 96% (Figure 2). Similar rates of major cytogenetic response were observed in resistant- and intolerant- patients. This is likely due to the rigorous definition of imatinib intolerance, which excluded imatinib-intolerant patients who had achieved a prior major cytogenetic response (thus the imatinib-intolerant patients had -also relatively less sensitive disease-)."